[Rituximab induced remission of pemphigus vulgaris: 2 cases]


Journal Article (Academic article)

INTRODUCTION: Pemphigus vulgaris frequently requires corticoids and immuno-suppressive drugs. The disease and the side effects of the drugs severely affect the quality of life, and sometime the vital prognosis of the patients. Other treatments than corticosteroids and immunosuppressive drugs are needed. EXEGESIS: We report 2 additional cases of pemphigus vulgaris uncontrolled by corticoids and immuno-suppressive drugs that responded spectacularly to rituximab. One patient had a recently onset disease, that was active despite 1,5 mg/kg/day prednisone and 1,5 g/day mycophenolate. She had a complete remission during 15 months after rituximab treatment. At relapse, another rituximab cycle led to a prompt remission. The other patient had longstanding pemphigus vulgaris complicated by cutaneous infections on prednisone (20 mg/d), immunosuppressive drugs and intravenous immune globulins. She had a prompt and complete remission after rituximab. CONCLUSION: Rituximab seems to be a promising drug for refractory pemphigus vulgaris. The benefit to risk ratio of this drug in this new indication must be precisely documented.

Duke Authors

Cited Authors

  • Borel, C; Launay, F; Garrouste, C; Astudillo, L; Bazex, J; Arlet, P; Paul, C; Viraben, R; Sailler, L

Published Date

  • April 2007

Published In

Volume / Issue

  • 28 / 4

Start / End Page

  • 266 - 268

International Standard Serial Number (ISSN)

  • 0248-8663

Conference Location

  • france